For patient investors, this could be the chance you’ve been waiting for to add this blue-chip name to your portfolio. Novo Nordisk’s GLP-1 drugs, Wegovy and Ozempic, helped propel the ...

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...

Novo Nordisk falls most on record after new weight drug disappoints Novo’s shares plunged as much as 27 per cent, and they’re now down 17 per cent for the year after a previous runup on the strength ...

This story was updated to add new information. The parent company of Danish drug maker Novo Nordisk said it completed its $16.5 billion purchase of Catalent, including the Bloomington operations ...

With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a concerted push to bolster its pipeline beyond GLP-1 stalwarts Ozempic ...

COPENHAGEN, Dec 17 — Danish health authorities said on Monday they would ask the European Union’s drug regulator to review the findings of two Danish studies linking Novo Nordisk’s popular diabetes ...

Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk (NYSE:NVO). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Subscribe here to receive future editions. There may be a new, unintended side effect linked to Novo Nordisk's blockbuster diabetes injection, Ozempic. Danish health authorities on Monday said ...

With Novo Nordisk A/S in the midst of a rapid hiring spree at its manufacturing hub, just half a mile away, finding staff to keep his small business running became virtually impossible.

Denmark-based pharma giant Novo Nordisk has announced plans to invest DKr8.5bn ($1.2bn) to establish a new production facility in Odense, Denmark. Announcing the news yesterday (16 December), the ...